DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 06035/S-078

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals, Corp.
Attention: Susan Kummerer, M.S.
Director, Drug Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Ms. Kummerer:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 26, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Methergine® (methylergonovine maleate tablet and injection).

We acknowledge receipt of your amendments dated November 9 and December 6, 2011, and April 5, May 4, and June 6, 2012.

This "Prior Approval" supplemental new drug application provides for the following changes to the Methergine® Prescribing Information and the issuance of the Dear Healthcare Provider letter.

In the Prescribing Information:

- Under WARNINGS section, the addition of the following:
  a. warning on not breast-feeding during Methergine treatment and for at least 12 hours after the last dose of Methergine
  b. warning on an increased risk of developing myocardial ischemia and infarction in patients with coronary artery disease or risk factors for coronary artery disease
  c. warning of the accidental administration of Methergine injection to newborn infants

- Under PRECAUTIONS section:
  a. Drug Interactions subsection: addition of drug interactions with CYP3A4 inducers, Beta-blockers, Anesthetics, and Glyceryl trinitrate and antianginal drugs
  b. Nursing Mothers subsection: addition of a warning on not breast-feeding during Methergine treatment and for at least 12 hours after the last dose of Methergine.

- Under ADVERSE REACTIONS section: the addition of Postmarketing Experience subsection containing reported adverse drug reactions related to nervous system and cardiac disorders.

In the Dear Healthcare Provider letter: information regarding accidental administration of Methergine injection to newborn infants.

Minor revisions were made to the language of the INDICATIONS AND USAGE section to improve readability and you have agreed to these changes.

We have completed our review of your supplement and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Meredith Alpert, Acting Safety Regulatory Project Manager, at (301) 796-1218.

Sincerely,

{See appended electronic signature page}

Christine Nguyen, M.D.
Acting Deputy Director for Safety
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Dear Heathcare Professional Letter

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
06/25/2012